Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177355 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT04177355 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 127 participants.
The verdict
NCT04177355, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL 3M-052-AF
- BIOLOGICAL BG505 SOSIP.664 gp140
- BIOLOGICAL CpG 1018
- BIOLOGICAL GLA-LSQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2024-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177355
The ClinicalTrials.gov registry entry for NCT04177355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04177355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177355 about?
NCT04177355 is a clinical study titled "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults". The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.
What is the current status of trial NCT04177355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2020-01-13. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT04177355?
The interventions under investigation include: Placebo (BIOLOGICAL), 3M-052-AF (BIOLOGICAL), BG505 SOSIP.664 gp140 (BIOLOGICAL), CpG 1018 (BIOLOGICAL), GLA-LSQ (BIOLOGICAL).
Who is sponsoring clinical trial NCT04177355?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.